非囊性纤维化支气管扩张症市场－全球产业规模、份额、趋势、机会和预测，依治疗方法、诊断、最终用途、地区和竞争格局划分，2020-2030年预测

2024年全球非囊性纤维化支气管扩张症市场规模为37.1亿美元，预计2030年将以5.30%的复合年增长率成长至50.6亿美元。全球非囊性纤维化支气管扩张症（NCFB）市场主要针对一种慢性肺部疾病，该疾病的特征是气道永久性扩张和增厚，与囊性纤维化不同，会导致粘液清除障碍和反覆呼吸道感染。该市场的主要驱动因素是全球慢性呼吸系统疾病盛行率的不断上升，以及诊断技术的显着进步，例如高解析度CT扫描，这些进步有助于更早、更准确地识别疾病。

主要市场驱动因素

非囊性纤维化支气管扩张症 (NCFB) 在全球范围内的日益流行，是推动市场发展的主要因素，直接提升了对诊断和治疗资源的需求。诊断技术的进步、临床医生认识的提高以及对 NCFB 多种病因的深入了解，都进一步推动了这一趋势。

主要市场挑战

针对非囊性纤维化支气管扩张症的特异性疾病改善疗法数量有限，这极大限制了市场扩张。目前的治疗方法主要着重于控制症状和併发症，例如反覆感染，而不是解决疾病的根本进展。

主要市场趋势

疾病修饰疗法和生物疗法的开发标誌着全球非囊性纤维化支气管扩张症市场发生了关键性转变，治疗重点从症状管理转向直接改变疾病进展的干预措施。这项转变的重点包括旨在减轻发炎或破坏细菌定植的先进生物製剂和小分子药物。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：客户之声

第五章：全球非囊性纤维化支气管扩张市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依治疗方法（手术、物理治疗、疫苗接种、气道药物治疗、抗生素、其他）
  • 依诊断方法（CT扫描、支气管镜检查、胸部X光检查、肺功能检查、痰液培养检查、血液检查、其他）
  • 依最终用途（医院和诊所、门诊中心、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美非囊性纤维化支气管扩张市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲非囊性纤维化支气管扩张市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区非囊性纤维化支气管扩张市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲非囊性纤维化支气管扩张市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲非囊性纤维化支气管扩张市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球非囊性纤维化支气管扩张市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Novartis AG
• Pfizer Inc.
• Bayer AG
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• GSK plc
• F. Hoffmann-La Roche Ltd.
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Ltd.
• Dr. Reddy's Laboratories Ltd.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Non-Cystic Fibrosis Bronchiectasis Market, valued at USD 3.71 Billion in 2024, is projected to experience a CAGR of 5.30% to reach USD 5.06 Billion by 2030. The Global Non-Cystic Fibrosis Bronchiectasis (NCFB) market addresses a chronic lung condition characterized by the permanent dilation and thickening of the airways, distinct from cystic fibrosis, which leads to impaired mucus clearance and recurrent respiratory infections. The market is primarily driven by the increasing global prevalence of chronic respiratory diseases, alongside significant advancements in diagnostic technologies, such as high-resolution CT scans, facilitating earlier and more accurate disease identification.

Key Market Drivers

The increasing global prevalence of non-cystic fibrosis bronchiectasis (NCFB) stands as a primary market driver, directly raising demand for diagnostic and therapeutic resources. This trend is fueled by advancements in diagnostic technologies, heightened clinician awareness, and a deeper understanding of NCFB's diverse etiologies. NCFB's chronic and progressive nature, often involving recurrent infections, necessitates continuous medical management. As diagnostic methods become more precise, leading to earlier identification, recorded prevalence rates steadily increase.

Key Market Challenges

The limited availability of specific, disease-modifying therapies for Non-Cystic Fibrosis Bronchiectasis significantly constrains market expansion. Current treatment approaches predominantly focus on managing symptoms and complications, such as recurrent infections, rather than addressing the underlying disease progression. This reliance on symptomatic or off-label treatments creates a substantial unmet medical need and restricts the development of a dedicated market segment for truly transformative interventions. Pharmaceutical companies face reduced incentives for significant investment in a therapeutic area where targets for disease modification are not well-defined or approved pathways are limited.

Key Market Trends

The development of disease-modifying and biologic therapies signifies a pivotal evolution in the Global Non-Cystic Fibrosis Bronchiectasis Market, shifting beyond symptomatic management to interventions that directly alter disease progression. This focus includes advanced biologic agents and small molecules designed to reduce inflammation or disrupt bacterial colonization. According to the American Thoracic Society (ATS) 2025 International Conference, in May 2025, the average initial hospitalization for NCFBE patients was 7.1 days, costing 22,355 USD, highlighting the substantial burden new treatments aim to alleviate.

Key Market Players

• Novartis AG
• Pfizer Inc.
• Bayer AG
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• GSK plc
• F. Hoffmann-La Roche Ltd.
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Ltd.
• Dr. Reddy's Laboratories Ltd.

Report Scope:

In this report, the Global Non-Cystic Fibrosis Bronchiectasis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Cystic Fibrosis Bronchiectasis Market, By Treatment:

• Surgery
• Physiotherapy
• Vaccination
• Airway pharmacotherapy
• Antibiotics
• Others

Non-Cystic Fibrosis Bronchiectasis Market, By Diagnosis:

• CT scan
• Bronchoscopy
• Chest X-ray
• Lung function
• Sputum culture test
• Blood tests
• Others

Non-Cystic Fibrosis Bronchiectasis Market, By End use:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Non-Cystic Fibrosis Bronchiectasis Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Non-Cystic Fibrosis Bronchiectasis Market.

Available Customizations:

Global Non-Cystic Fibrosis Bronchiectasis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Cystic Fibrosis Bronchiectasis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Surgery, Physiotherapy, Vaccination, Airway pharmacotherapy, Antibiotics, Others)
  • 5.2.2. By Diagnosis (CT scan, Bronchoscopy, Chest X-ray, Lung function, Sputum culture test, Blood tests, Others)
  • 5.2.3. By End use (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Non-Cystic Fibrosis Bronchiectasis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Diagnosis
  • 6.2.3. By End use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Diagnosis
      • 6.3.1.2.3. By End use
  • 6.3.2. Canada Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Diagnosis
      • 6.3.2.2.3. By End use
  • 6.3.3. Mexico Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Diagnosis
      • 6.3.3.2.3. By End use

7. Europe Non-Cystic Fibrosis Bronchiectasis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Diagnosis
  • 7.2.3. By End use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Diagnosis
      • 7.3.1.2.3. By End use
  • 7.3.2. France Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Diagnosis
      • 7.3.2.2.3. By End use
  • 7.3.3. United Kingdom Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Diagnosis
      • 7.3.3.2.3. By End use
  • 7.3.4. Italy Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By Diagnosis
      • 7.3.4.2.3. By End use
  • 7.3.5. Spain Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By Diagnosis
      • 7.3.5.2.3. By End use

8. Asia Pacific Non-Cystic Fibrosis Bronchiectasis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Diagnosis
  • 8.2.3. By End use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Diagnosis
      • 8.3.1.2.3. By End use
  • 8.3.2. India Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Diagnosis
      • 8.3.2.2.3. By End use
  • 8.3.3. Japan Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Diagnosis
      • 8.3.3.2.3. By End use
  • 8.3.4. South Korea Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By Diagnosis
      • 8.3.4.2.3. By End use
  • 8.3.5. Australia Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By Diagnosis
      • 8.3.5.2.3. By End use

9. Middle East & Africa Non-Cystic Fibrosis Bronchiectasis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Diagnosis
  • 9.2.3. By End use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Diagnosis
      • 9.3.1.2.3. By End use
  • 9.3.2. UAE Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Diagnosis
      • 9.3.2.2.3. By End use
  • 9.3.3. South Africa Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Diagnosis
      • 9.3.3.2.3. By End use

10. South America Non-Cystic Fibrosis Bronchiectasis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment
  • 10.2.2. By Diagnosis
  • 10.2.3. By End use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By Diagnosis
      • 10.3.1.2.3. By End use
  • 10.3.2. Colombia Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By Diagnosis
      • 10.3.2.2.3. By End use
  • 10.3.3. Argentina Non-Cystic Fibrosis Bronchiectasis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By Diagnosis
      • 10.3.3.2.3. By End use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Non-Cystic Fibrosis Bronchiectasis Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Bayer AG
• 15.4. Viatris Inc.
• 15.5. Teva Pharmaceutical Industries Ltd.
• 15.6. GSK plc
• 15.7. F. Hoffmann-La Roche Ltd.
• 15.8. Sun Pharmaceutical Industries Ltd.
• 15.9. Aurobindo Pharma Ltd.
• 15.10. Dr. Reddy's Laboratories Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer